C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study (Q46061278)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19346228

C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19346228

0 references

0 references

myocardial infarction

1 reference

based on heuristic

inferred from title

Stephan von Haehling

2

object named as

Stephan von Haehling

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

Stefan D. Anker

3

object named as

Stefan D Anker

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

Dirk J van Veldhuisen

9

object named as

Dirk J van Veldhuisen

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19346228

Kenneth Dickstein

10

object named as

Kenneth Dickstein

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19346228

4

object named as

Hans L Hillege

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19346228

Adriaan A Voors

1

object named as

Adriaan A Voors

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19346228

5

object named as

Joachim Struck

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19346228

8

object named as

Iain Squire

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19346228

author name string

Oliver Hartmann

6

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19346228

Andreas Bergmann

7

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19346228

OPTIMAAL Investigators

11

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19346228

publication date

3 April 2009

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19346228

European Heart Journal

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19346228

30

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19346228

10

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19346228

1187-1194

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19346228

Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP098

21 January 2018

Influence of age on natriuretic peptides in patients with chronic heart failure: a comparison between ANP/NT-ANP and BNP/NT-proBNP.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP098

21 January 2018

Plasma brain natriuretic peptide concentration: impact of age and gender

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP098

21 January 2018

C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP098

21 January 2018

Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP098

21 January 2018

Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP098

21 January 2018

Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP098

21 January 2018

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP098

21 January 2018

Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP098

21 January 2018

Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP098

21 January 2018

Vasopressin antagonism in heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP098

21 January 2018

Vasopressin: a new target for the treatment of heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP098

21 January 2018

Vasopressin and vasopressin receptor antagonists in heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP098

21 January 2018

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP098

21 January 2018

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP098

21 January 2018

Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP098

21 January 2018

Use of copeptin in the detection of myocardial ischemia

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP098

21 January 2018

Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP098

21 January 2018

Identifiers

10.1093/EURHEARTJ/EHP098

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19346228

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19346228

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46061278&oldid=2089856112"